VRCA Logo

Verrica Pharmaceuticals Inc. (VRCA) 

NASDAQ
Market Cap
$62.87M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
21 of 960
Rank in Industry
16 of 550

Largest Insider Buys in Sector

VRCA Stock Price History Chart

VRCA Stock Performance

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration …

Insider Activity of Verrica Pharmaceuticals Inc.

Over the last 12 months, insiders at Verrica Pharmaceuticals Inc. have bought $25.98M and sold $1.08M worth of Verrica Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Verrica Pharmaceuticals Inc. have bought $12.4M and sold $1.11M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Manning Paul B () — $102M. PERCEPTIVE ADVISORS LLC (10 percent owner) — $100.1M. Stalfort John A III (director) — $3M.

The last purchase of 22,921,348 shares for transaction amount of $20.4M was made by Manning Paul B () on 2024‑11‑22.

List of Insider Buy and Sell Transactions, Verrica Pharmaceuticals Inc.

2024-11-22Purchase
22.92M
45.1241%
$0.89$20.4M-0.35%
2024-11-22Purchasedirector
1.12M
2.212%
$0.89$1,000,000-0.35%
2024-11-22PurchaseCEO and President
280,898
0.553%
$0.89$249,999-0.35%
2024-08-27SalePRESIDENT AND CEO
9,021
0.0211%
$2.46$22,192-45.53%
2024-08-27SaleCHIEF LEGAL OFFICER
9,530
0.0223%
$2.46$23,444-45.53%
2024-08-27SaleChief Medical Officer
3,601
0.0084%
$2.46$8,858-45.53%
2024-08-27SaleCHIEF COMMERCIAL OFFICER
8,993
0.0211%
$2.46$22,123-45.53%
2024-08-27SaleCHIEF FINANCIAL OFFICER
7,899
0.0185%
$2.46$19,432-45.53%
2024-08-26SalePRESIDENT AND CEO
24,979
0.0606%
$2.66$66,444-47.86%
2024-08-26SaleCHIEF LEGAL OFFICER
26,183
0.0635%
$2.66$69,647-47.86%
2024-08-26SaleChief Medical Officer
9,888
0.024%
$2.66$26,302-47.86%
2024-08-26SaleCHIEF COMMERCIAL OFFICER
24,709
0.0599%
$2.66$65,726-47.86%
2024-08-26SaleCHIEF FINANCIAL OFFICER
21,820
0.0529%
$2.66$58,041-47.86%
2024-07-23SalePRESIDENT AND CEO
154
0.0003%
$6.98$1,075+1.86%
2024-07-23SaleCHIEF LEGAL OFFICER
91
0.0002%
$6.98$635+1.86%
2024-07-23SaleChief Medical Officer
86
0.0002%
$6.98$600+1.86%
2024-07-23SaleCHIEF COMMERCIAL OFFICER
115
0.0003%
$6.98$803+1.86%
2024-07-22SalePRESIDENT AND CEO
32,469
0.0765%
$7.06$229,231-78.97%
2024-07-22SaleCHIEF LEGAL OFFICER
21,649
0.051%
$7.06$152,842-78.97%
2024-07-22SaleChief Medical Officer
18,421
0.0434%
$7.06$130,052-78.97%

Insider Historical Profitability

13.24%
Manning Paul B
26278094
29.0158%
$0.69190+7.38%
PERCEPTIVE ADVISORS LLC10 percent owner
7099182
7.8388%
$0.69100<0.0001%
Stalfort John A IIIdirector
1823800
2.0138%
$0.6950+51.41%
Rieger JaysonCEO and President
832826
0.9196%
$0.6910
White TedPRESIDENT AND CEO
215967
0.2385%
$0.6977+0.47%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$42.03M16.747.1M0%+$00.03
Avoro Capital Advisors Llc$23.68M9.434M0%+$00.28
Fidelity Investments$8.93M3.561.51M+0.01%+$1,101.12<0.01
The Vanguard Group$7.51M2.991.27M+0.6%+$45,045.28<0.0001
BlackRock$6.6M2.631.11M-1.91%-$128,363.38<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.